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Abstract
Background: Previous preliminary reports have suggested potential interactions between
microcytic anaemia and mood disorders. In particular, heterozygous β-thalassaemia has been
implicated in the bipolar spectrum. This study surveyed relevant haematological parameters in a
large sample of psychiatric outpatients with the aim of clarifying previous observations.
Methods: Mean Corpuscular Volume (MCV) was analysed in 1014 consecutive patients diagnosed
according to modified Research Diagnostic Criteria (RDC). Haemoglobin electrophoresis and/or
chromatography was performed in blood samples from 143 patients with reduced MCV.
Prevalence of heterozygous β-thalassaemia was estimated based on the rates of patients with
reduced MCV and increased haemoglobin A2 concentration.
Results: MCV lower than 80 µ3 was found in greater proportions among bipolar compared with
the remaining RDC subgroups (183/732 = 25.0% versus 51/282 = 18.1%; p = 0.02; relative risk =
1.38; Fisher's exact test). This difference can mainly be attributed to heterozygous β-thalassaemia,
the estimated prevalence of which was 16.4% among bipolar and 9.9% among non-bipolar
subgroups (p = 0.01; relative risk = 1.65).
Conclusion: The results are consistent with the hypothesis that heterozygous β-thalassaemia
might play a role as a susceptibility factor in bipolar spectrum disorders in specific populations.
Background
Our interest in potential interactions between mood dis-
orders of the bipolar spectrum and blood conditions typ-
ical of the Mediterranean area, such as glucose-6-
phosphate dehydrogenase (G6PD) deficiency and hetero-
zygous β-thalassaemia, was first aroused in the 1980 s. At
that time, chromosomes Xq28 and 11p15, where the
G6PD gene and the β-globin gene cluster are located,
became very popular in psychiatric genetics following the
reports of positive linkage with manic-depression [1-3].
We subsequently surveyed G6PD deficiency and hetero-
zygous β-thalassaemia as phenotypic markers to be used
in linkage studies [4]. Unexpectedly, we found excessive
proportions of the two markers among bipolar patients,
especially those with psychotic symptoms [5-7]. Among
potential mechanisms underlying the observed associa-
tions, we considered linkage disequilibrium between the
markers and mood disorder genes located in Xq28 and
11p15. This hypothesis, which at first was most intrigu-
ing, weakened considerably when subsequent studies
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[8,9]. Over the following years, the use of phenotypic
markers in psychiatric genetics vanished due to the advent
of molecular DNA markers. Nevertheless, with regard to
heterozygous β-thalassaemia, our interest was periodi-
cally revived by the appearance of relevant reports. On the
one hand, co-occurrence of the thalassaemic trait and
bipolar disorder was reported in several cases from vari-
ous countries, including Japan, where thalassaemia is very
rare [10-13]. On the other hand, a psychiatric population
surveyed in Argentina revealed excessive prevalence of
microcytic anaemia among patients suffering from recur-
rent mood disorder [14]. Given the latter series of intrigu-
ing reports, an extension of our previous surveys was
warranted: this is an updated account of haematological
parameters regarding 1014 patients.
Methods
Outpatients consecutively admitted to the Department of
Neuroscience, University of Cagliari, between 1980 and
2000 were studied. The department is one of the reference
centres for the management of lithium and related treat-
ments of mood disorders in southern Sardinia. On admis-
sion, detailed information was obtained from the patient
and from other available sources (such as relatives and
referring clinicians) concerning demographic characteris-
tics and lifetime medical and psychiatric history. Moreo-
ver, all available records regarding previous prescriptions
or hospitalisations were examined. Psychiatric diagnosis
was made according to modified Research Diagnostic Cri-
teria (RDC) [15,7]. Routine laboratory tests, including
blood count and serum iron concentration were available
for 1014 patients. All subjects gave their informed consent
to participate in the study.
Additional procedures were used aiming at the identifica-
tion of heterozygous β-thalassaemia, which is ordinarily
diagnosed based on reduced MCV, increased haemo-
globin A2 (HbA2), and normal serum iron concentration.
In an initial survey [5], haemoglobin electrophoresis was
systematically performed in samples from 180 patients
who had attended the centre between April 3rd and May
3rd, 1989. Thereafter, MCV lower than 80 µ3 was chosen
as the cut-off for the performing of haemoglobin electro-
phoresis and/or chromatography (98% of cases with
abnormally high HbA2 concentration from the initial sur-
vey had MCV<80 µ3). Overall, electrophoresis and/or
chromatography were obtained for 143 patients with
MCV<80 µ3. Of the latter, 62% had increased HbA2 (het-
erozygous β-thalassaemia); 22% had normal HbA2 and
normal serum iron (in Sardinia, this pattern has been
characterised molecularly as heterozygous α-thalassaemia
in the large majority of cases [16]). In the remaining 16%,
HbA2 concentration was normal but serum iron was
reduced, therefore heterozygous β-thalassaemia could not
be ruled out (iron-deficiency may maintain HbA2 within
the normal range).
Results
Overall, MCV<80 µ3 was found in 23.1% of patients
(Table 1). Greater proportions were found among sub-
groups with bipolar course compared with the remaining
subgroups (p = 0.02 at the Fisher's exact test; 183/732 =
25.0% versus 51/282 = 18.1%; relative risk = 1.38). The
highest proportion was found in Manic Schizoaffective
disorder, predominantly affective subtype (74/219 =
33.8%).
Heterozygous β-thalassaemia (increased HbA2 concentra-
tion) accounted for the majority of patients with MCV<80
µ3. Rates did not vary between the initial survey (27/42 =
64%) and subsequent cases who underwent HbA2 analy-
sis (62/101 = 62%). If similar rates were assumed regard-
ing the remaining 91 patients with MCV<80 µ3 but
unknown HbA2 concentration, prevalence of hetero-
zygous β-thalassaemia in the overall sample could be esti-
Table 1: Reduced Mean Corpuscular Volume (MCV) and Heterozygous β-Thalassaemia in 1014 Psychiatric Outpatients
RDC Diagnosis Number of Patients MCV<80 µ3 N (%) Heterozygous β-Thalassaemiaa
Definite Probable Total (%)
Manic Schizoaffective 288 88 (30.6) 42 16 58 (20.1)
Bipolar with Mania 269 59 (21.9) 17 21 38 (14.1)
Bipolar with Hypomania 175 36 (20.6) 16 8 24 (13.7)
Depressive Schizoaffective 96 19 (19.8) 6 4 10 (10.4)
Recurrent Major Depression 124 24 (19.4) 7 7 14 (11.3)
Other (Schizophrenia, Minor Depression, etc) 62 8 (12.9) 1 3 4 (6.5)
TOTAL 1014 234 (23.1) 89 59 148 (14.6)
aRates of heterozygous β-thalassaemia are estimated based on the number of definite cases (MCV <80 µ3 and increased HbA2) plus the number of 
probable cases (62 % of patients with MCV <80 µ3 but unknown HbA2).Page 2 of 4
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non-bipolar subgroups. A simulation of the Fisher's exact
test provided a bipolar/non-bipolar relative risk of 1.65
with a p value of 0.01. Estimated rates of heterozygous β-
thalassaemia across psychiatric diagnoses are shown in
Table 1. The subgroup of patients with Manic Schizoaffec-
tive disorder, predominantly affective subtype (not
shown), had the highest estimated rate of heterozygous β-
thalassaemia (22%).
The distribution of patients with MCV<80 µ3 and normal
HbA2 concentration did not vary across psychiatric diag-
noses (not shown).
Discussion
Reduced Mean Corpuscular Volume and Mood Disorder
In this survey, an impressive 24% of the 952 patients suf-
fering from major mood disorders had an MCV lower
than 80 µ3. Rates of reduced MCV were lower (13%) in the
small subgroup of patients (N = 62) with other psychiatric
diagnoses. The direction of results strikingly parallels that
from an Argentinean survey [14], which reported a 17.7 %
prevalence of microcytic anaemia among 79 patients with
recurrent mood disorders compared with 8.0 % preva-
lence among 25 patients with other psychiatric diagnoses
(schizophrenia, anxiety, etc). The lack of similar studies in
the literature is surprising given the number of symptoms
shared between anaemia and depression (fatigue, asthe-
nia, somatic complaints, etc). On the contrary, many stud-
ies have investigated macrocytic anaemia and the effects
of vitamin B12 deficiency in the CNS.
Prevalence of reduced MCV appeared to follow a hierar-
chy across the spectrum of mood disorders, according to
the presence of psychotic and manic features. Since sever-
ity of symptoms may reflect an increased underlying bio-
logical/genetic load, the hypothesis of microcytic anaemia
as a susceptibility factor is warranted.
Heterozygous β-Thalassaemia and Mood Disorder
In this survey, variation in prevalence of reduced MCV by
psychiatric diagnosis was mostly attributable to hetero-
zygous β-thalassaemia. Data substantially confirmed
those from our initial 1989 survey [5], in which haemo-
globin electrophoresis was systematically performed in
blood samples from 180 patients. The highest rates of het-
erozygous β-thalassaemia had been found in Manic
Schizoaffective Disorder and an apparent bipolar/non-
bipolar distinction had already been signalled. In this
extended sample, the estimated rates were 16.4 % in bipo-
lar and 9.9 % in non-bipolar subgroups. Results paral-
leled those from the above mentioned Argentinean survey
[14], where heterozygous β-thalassaemia was diagnosed
in four of the 51 bipolar patients (7.8 %) and in only one
of the 53 remaining cases (1.9 %). Prevalence in the gen-
eral population in Argentina has been estimated at
approximately 5% [14], even if geographical variation is
assumed reflecting non-homogeneous ethnic distribu-
tion. In Sardinia, 12.6 % is the rate found in the general
population [17], but a wide variation has been reported
following once malarial morbidity [18].
Potential geographical stratification is a relevant point in
the interpretation of our findings: in fact, if mood disor-
der with psychotic and/or manic features is more preva-
lent for unknown reasons in once malarial areas in
Sardinia, a spurious association with heterozygous β-tha-
lassaemia might have derived. The latter possibility is
however challenged by the similarity in results between
two independent studies (ours and the Argentinean one).
Another approach capable of ruling out a potential geo-
graphical bias is the study of segregation between marker
and disease within families, given the shared origin of rel-
atives. Indeed, we found a higher than expected concord-
ance between mood disorder and the blood condition
within families of our patients with heterozygous β-tha-
lassaemia (to be reported in a different account). A ten-
dency towards familial co-segregation was also inferable
by pooling data from published case reports of bipolar
disorder and heterozygous β-thalassaemia ascertained in
Canada [10], Eire [11], Japan [12], and Australia [13].
In the presence of a true genetic association, different
mechanisms may be hypothesised, including linkage dis-
equilibrium between the globin gene and a mood disor-
der gene closely located in chromosome 11p15 or a direct
effect of heterozygous β-thalassaemia in clinical presenta-
tion or severity of mood disorder.
Whatever the mechanism, the relevance of heterozygous
β-thalassaemia as a susceptibility factor in mood disorder
can be inferred from two recently published studies from
India [19] and Greece [20]. Since the context was that of
studies of psychosocial adjustment of parents of (or at risk
of bearing) children with Cooley's anaemia, attention was
mostly directed to current depression and anxiety (rather
than to history of bipolar or schizoaffective disorder, if
any). Moreover, the potential role of the mild or silent
blood condition in parents was not taken into account. In
the Indian study [19], depression was diagnosed in 70%
of parents (19 mothers and 11 fathers) accompanying
their thalassaemic child for blood transfusion. Unfortu-
nately no group of parents of children suffering from
other severe chronic diseases was included for
comparison.
The Greek study [20] reported clinically relevant depres-
sion in 10.1% of 159 women with heterozygous β-thalas-
saemia undergoing chorionic villus sampling due to
increased possibility of carrying an embryo with Cooley'sPage 3 of 4
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anaemia (spouses were β-thalassaemic carriers too). As
comparison groups, 150 women undergoing karyotyping
for risk of trisomy and 309 undergoing a routine first tri-
mester scan were studied. Depression was found in 4.7 %
and 0.3 %, respectively.
In another Greek study [21], more psychiatric disorders,
including a broad range of DSM-III-R diagnoses, were
found among 71 siblings of subjects with Cooley's anae-
mia compared with 71 control subjects. In the age group
from 10 to 19 years, the difference was significant (61%
compared with 37%). Even if the latter data are intriguing,
no conclusion can be drawn regarding the role of hetero-
zygous β-thalassaemia in this sample, because haemato-
logical data of participants were not envisaged. However,
since the expected proportion of thalassaemic carriers
among siblings of subjects with Cooley's anaemia is 2/3,
similar samples would be very informative. Inclusion of
older age groups, when mood disorders are better charac-
terised, would be preferable.
Conclusion
The results from this survey and the series of intriguing lit-
erature reports are consistent with the hypothesis that het-
erozygous β-thalassaemia might play a role as a
susceptibility factor in mood disorders, particularly of the
bipolar spectrum. Since the evidence cannot be consid-
ered established, further studies are warranted. Potential
approaches include: a) replication surveys of microcytic
anaemia and the thalassaemic trait in psychiatric popula-
tions from high prevalence areas; b) surveys of bipolar
spectrum disorders among subjects with an already estab-
lished diagnosis of heterozygous β-thalassaemia (such as
relatives of patients with Cooley's anaemia or participants
in specific screening programs); c) family studies of
patients with bipolar disorder and an established thalas-
saemic trait.
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